Interviews

Adam J. Fein describes how the 340B program is being exploited by many hospital systems due to a lack of oversight by government agencies.

Einodshofer explains how the costs associated with one specialty patient's treatment can have the same financial footprint as an entire population of patients. Video from PBMI's Drug Benefit Conference 2013.

In this video from the 2013 Armada Specialty Pharmacy Summit in Las Vegas, Nevada, Adam J. Fein of Pembroke Consulting Inc and Drug Channels discusses the boom in new specialty pharmacy trade associations and describes the impact that competition amongst specialty pharmacy providers could have on the industry.

Health Reform and You

By

Troy Trygstad, PharmD, PhD, MBA, co-editor of the Directions in Pharmacy supplements, discusses the evolving health care landscape and how pharmacists can navigate it.

Access to Innovation

By

In this video, executives from AstraZeneca and MedImmune explain why access to innovation in the development of biologics is so important.

William A. Scott, MD, addresses the question of whether children who are initiating use of ADHD medication need to have an EKG.

Treating ADHD

By

Pediatrician Preeti Parikh, MD, provides an introduction to treatments for ADHD in children, including behavioral therapy, psychotherapy, family therapy, and various types of medication.

A lecture on acute coronary syndromes by Kim A. Eagle, MD, director of the Cardiovascular Center at the University of Michigan Health System.

An animated video demonstrating how influenza virus enters a human cell, penetrates the nucleus, replicate itself, and emerges to infect other cells.

A discussion of efforts to develop a universal influenza vaccine that will be capable of protecting against any potential strain of the influenza virus.

This video from the National Institute of Allergy and Infectious Diseases discusses the causes of influenza pandemics.

HIV Treatment Cascade Model

By

FHI 360 President Emeritus Ward Cates discusses the HIV treatment cascade. This model aims to bring us closer to the end of AIDS by addressing the gaps in the HIV diagnosis and treatment system currently in place.

HIV Drug Development

By

Arun K. Ghosh. professor of organic and medicinal chemistry at Purdue University, talks with Hiroaki Mitsuya, Head of Experimental Retrovirology Section at the National Cancer Institute, about HIV drug development.